Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Vyant Bio, Inc. VYNT NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
19/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Vyant Bio, Inc. (VYNT) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.

VYNT Analyst Ratings

Hold
1
Ratings
1 Hold
Based on 1 analysts giving stock ratings to Vyant Bio, Inc. in the past 3 months
Rating breakdown
Hold
1 100%
0%
Buy
0 analysts
100%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

FBRX
FBRX
Forte Biosciences, Inc.
$32.42
+5.95%
 DMAC
DMAC
DiaMedica Therapeutics Inc.
$6.54
+3.81%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 SRZN
SRZN
Surrozen, Inc.
$31.07
+4.05%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ALGS
ALGS
Aligos Therapeutics, Inc.
$8.55
-1.04%
 NTRB
NTRB
Nutriband Inc.
$4.06
+2.01%
 SABS
SABS
SAB Biotherapeutics, Inc.
$3.86
-1.03%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message